| Wissenschaftl. Titel | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR) |
| Erkrankung |
Thorax:
Nicht-kleinzelliges Lungenkarzinom:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Information (NIH) Weiterführende Information (EudraCT) |
erstellt 08.03.2023 Data entry III CCP
geändert 29.02.2024 Data entry III CCP